The federal government told drug manufacturer Merck today its conditions on 340B pricing when hospitals and health centers use contract pharmacies are illegal and must stop, or the company could face penalties of up to $6,323 per each
…
Emeka Egwim, a federal government HIV/AIDS policy specialist who also has served in the Medicaid Drug Rebate Program, is the new head of the federal 340B Drug Pricing Program.
A federal district judge in Wilmington, Del., today struck down and vacated the federal government’s finding that drug maker AstraZeneca’s conditions on 340B pricing when covered entities uses contract pharmacies violates the 340B statute.
For the first time since the 340B contract pharmacy impasse started over a year and half ago, the leader of an influential hospital group said publicly today her association is prepared to move in the direction of a federal legislative
…
Bristol Myers Squibb (BMS) yesterday became the 12th drug manufacturer to impose restrictions on 340B pricing when hospitals and grantee covered entities contract with pharmacies to dispense drugs to patients.
AbbVie today announced conditions on 340B pricing when hospitals’ contract pharmacies dispense medicines to patients. The federal government has filed notices of appeal in Lilly, Novartis, Novo Nordisk, Sanofi, and United Therapeutics’ 340B contract pharmacy lawsuits.
The federal government late yesterday filed notice that it is appealing a federal judge’s joint ruling in two cases last month that halted enforcement actions against two drug companies that deny 340B pricing when hospitals and other health care providers
…
Biopharmaceutical manufacturer Amgen this morning became the 10th pharmaceutical to announce conditions on 340B pricing when contract pharmacies dispense medicines to patients.
A federal district judge last night issued the second court ruling of the day involving drug manufacturers’ denials of and limitations on 340B pricing when covered entities use contract pharmacies. Like the day’s earlier ruling, this one too was mixed,
…
A federal district judge this afternoon upheld the federal government’s finding that drug manufacturers Sanofi and Novo Nordisk cannot unilaterally impose restrictions on offers of 340B pricing to covered entities and that their policies must cease. But she also vacated
…